1. Home
  2. GAMB vs CTNM Comparison

GAMB vs CTNM Comparison

Compare GAMB & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GAMB
  • CTNM
  • Stock Information
  • Founded
  • GAMB 2006
  • CTNM 2009
  • Country
  • GAMB Jersey
  • CTNM United States
  • Employees
  • GAMB N/A
  • CTNM N/A
  • Industry
  • GAMB Services-Misc. Amusement & Recreation
  • CTNM
  • Sector
  • GAMB Consumer Discretionary
  • CTNM
  • Exchange
  • GAMB Nasdaq
  • CTNM Nasdaq
  • Market Cap
  • GAMB 273.9M
  • CTNM 328.1M
  • IPO Year
  • GAMB 2021
  • CTNM 2024
  • Fundamental
  • Price
  • GAMB $4.98
  • CTNM $10.93
  • Analyst Decision
  • GAMB Strong Buy
  • CTNM Strong Buy
  • Analyst Count
  • GAMB 7
  • CTNM 5
  • Target Price
  • GAMB $11.83
  • CTNM $20.40
  • AVG Volume (30 Days)
  • GAMB 1.2M
  • CTNM 166.5K
  • Earning Date
  • GAMB 11-13-2025
  • CTNM 10-30-2025
  • Dividend Yield
  • GAMB N/A
  • CTNM N/A
  • EPS Growth
  • GAMB N/A
  • CTNM N/A
  • EPS
  • GAMB 0.05
  • CTNM N/A
  • Revenue
  • GAMB $154,519,000.00
  • CTNM N/A
  • Revenue This Year
  • GAMB $38.41
  • CTNM N/A
  • Revenue Next Year
  • GAMB $11.58
  • CTNM N/A
  • P/E Ratio
  • GAMB $104.71
  • CTNM N/A
  • Revenue Growth
  • GAMB 24.21
  • CTNM N/A
  • 52 Week Low
  • GAMB $4.60
  • CTNM $3.35
  • 52 Week High
  • GAMB $17.14
  • CTNM $16.25
  • Technical
  • Relative Strength Index (RSI)
  • GAMB 24.44
  • CTNM 47.95
  • Support Level
  • GAMB $4.60
  • CTNM $10.46
  • Resistance Level
  • GAMB $7.02
  • CTNM $13.09
  • Average True Range (ATR)
  • GAMB 0.32
  • CTNM 0.98
  • MACD
  • GAMB -0.15
  • CTNM 0.08
  • Stochastic Oscillator
  • GAMB 15.40
  • CTNM 29.68

About GAMB Gambling.com Group Limited

Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Share on Social Networks: